HCWB HCW Biologics Inc. Insider Trading

CEO Hing C Wong buys 113,879 shares at $1.40 via placement; holds 615,790 post-transaction amid poor track record.

Hing C Wong, CEO, purchased 113,879 shares at $1.40 on 2026-05-22 for $160,000.00, increasing holdings to 615,790 shares (+22.7%). However, this transaction is flagged as a private placement or registered direct offering, not a discretionary open-market purchase, so it should not be read as a conviction-driven buying signal. Wong's cross-ticker track record shows 3 prior open-market buys with an average 90-day return of -62.2% and a 90d win rate of 0.00%, while his same-ticker history at HCWB shows two prior buys (2025-05-16 and 2025-05-08) both resulted in significant losses over 90 days (-41.7% and -82.6% respectively). HCW Biologics faces material headwinds: annual revenue growth was -97.9%, full-year net income was negative, and the company's market cap is only $13.1M against quarterly revenue of $6.5M. The stock is currently -78.0% from its 52-week high of $8.82, though it has rallied +341.9% over the past 30 days. A cluster of 2 other insiders also bought within 14 days, but the non-discretionary nature of this placement and the insider's poor historical timing at this ticker limit the significance of this filing.

Director Scott Garrett acquired 177,936 shares of HCWB via private placement at $1.40 (−78% from 52-week high), expanding holdings 697.7% to 203,441 shares

Scott T Garrett, a director of HCW Biologics, acquired 177,936 shares totaling $250,000.08 in a private placement transaction on 2026-05-22 at $1.40 per share. Because this is flagged as a private placement rather than a discretionary open-market purchase, it does not reflect conviction-driven buying. Garrett's prior two purchases at this ticker (2025-05-16 and 2025-05-08) both generated negative 90-day returns of −26.8% and −76.8%, with a zero win rate on timing at the 90-day mark. The company reported annual revenue growth of −97.9% and was unprofitable over its most recent full fiscal year, with market cap of $13.1M—a distressed financial profile that underscores the speculative character of this equity position. While the 30-day stock movement of +341.9% reflects recent volatility, the stock remains −78.0% from its 52-week high, signaling structural weakness rather than fundamental recovery.

CFO Rebecca Byam buys 14,235 shares at $1.40 in HCWB private placement; prior cross-ticker buys averaged -76.8% 30d return, 0 win rate.

Rebecca Byam, CFO of HCW Biologics Inc., purchased 14,235 shares at $1.40 on 2026-05-22 through a private placement (not a discretionary open-market buy), increasing her holdings by 33.1% to 57,245 shares post-transaction. This transaction cannot be interpreted as a buying signal driven by insider conviction, given the private-placement structure flagged in the filing. Her cross-ticker track record across 7 prior open-market buys shows an average 30-day return of -76.8% and average 90-day return of -82.6%, with a 0.00% 90-day win rate, suggesting a pattern of poorly timed purchases historically. The current stock price of $1.94 sits 78.0% below the 52-week high and has surged 341.9% over the past 30 days from a depressed base, but this price recovery does not align with her prior execution outcomes at the company. Finally, the company reported annual revenue growth of -97.9% and was unprofitable over its most recent full fiscal year, creating a fundamental backdrop of significant business contraction that warrants monitoring of whether the private placement reflects capital needs or strategic repositioning.